Aptose reports Q3 net loss $9.8M; tuspetinib completes dose escalation with CRs in FLT3+ AML

Aptose Biosciences Inc.

2022-Q3 EPS reported -$0.34

Net loss $9.8M ($0.11/share) vs $11.3M ($0.13) in Q3 2021; cash $55.4M funds operations into Q1 2024.
Tuspetinib (HM43239) completes Phase 1/2 dose escalation; 120mg selected for single-agent expansion, 80mg with venetoclax.
FLT3-mutant patients with prior FLT3 inhibitor failure achieved complete remissions; responses also in FLT3 wildtype with TP53/NRAS.
Luxeptinib G3 formulation shows ~18-fold bioavailability improvement; continuous dosing of 50mg Q12h to start shortly.
USAN Council adopted generic name 'tuspetinib'; Aptose will use for all future references.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptose Biosciences Inc. reported the quarter ended September 30, 2022 results: revenue $ -, net income $9.8 million, EPS ($0.11 per share).

Period: the quarter ended September 30, 2022
Revenue: $ -
Net income: $9.8 million
EPS: ($0.11 per share)
Result: reported results

Exact text from the filing

The net loss for the quarter ended September 30, 2022 was $9.8 million ($0.11 per share) compared with $11.3 million ($0.13 per share) for the quarter ended September 30, 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptose Biosciences Inc. reported the nine months ended September 30, 2022 results: revenue $ -, net income $31.8 million, EPS $ (0.34).

Period: the nine months ended September 30, 2022
Revenue: $ -
Net income: $31.8 million
EPS: $ (0.34)
Result: reported results

Exact text from the filing

Net loss for the nine-month period ended September 30, 2022 decreased by $9.2 million to $31.8 million, as compared to $41.0 million for the comparable period in 2021.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-006960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.